ganglioneuroblastoma (Cancer)
Information
- Disease name
- ganglioneuroblastoma
- Disease ID
- DOID:4163
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01798004 | Active, not recruiting | Phase 1 | Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | April 8, 2013 | |
| NCT03786783 | Active, not recruiting | Phase 2 | Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | March 4, 2019 | September 22, 2024 |
| NCT02311621 | Active, not recruiting | Phase 1 | Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 | November 25, 2014 | November 2038 |
| NCT03126916 | Active, not recruiting | Phase 3 | Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | May 14, 2018 | September 30, 2026 |
| NCT01175356 | Active, not recruiting | Phase 1 | Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin | October 4, 2010 | September 28, 2024 |
| NCT02176967 | Active, not recruiting | Phase 3 | Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma | August 8, 2014 | September 30, 2026 |
| NCT01767194 | Completed | Phase 2 | Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma | February 12, 2013 | September 30, 2022 |
| NCT06296732 | Recruiting | Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification | October 19, 2023 | November 1, 2031 | |
| NCT02112617 | Recruiting | N/A | Phase II Study of Proton Radiation Therapy for Neuroblastoma | June 2014 | March 2028 |
| NCT04040088 | Recruiting | Early Phase 1 | An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors | September 23, 2019 | July 2024 |
| NCT05192980 | Recruiting | N/A | SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic Tumours | November 2, 2023 | November 2, 2038 |
| NCT06071897 | Recruiting | Phase 3 | Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma | September 1, 2023 | September 1, 2029 |
| NCT00904241 | Recruiting | Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma | November 6, 2000 |
- Disase is a (Disease Ontology)
- DOID:769
- Cross Reference ID (Disease Ontology)
- ICDO:9490/3
- Cross Reference ID (Disease Ontology)
- MESH:D018305
- Cross Reference ID (Disease Ontology)
- NCI:C3790
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:116381000119105
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0206718
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0006747
- OrphaNumber from OrphaNet (Orphanet)
- 251877
- MeSH unique ID (MeSH (Medical Subject Headings))
- D018305